uniQure (NASDAQ:QURE) Shares Up 4.7% – What’s Next?

uniQure (NASDAQ:QURE)’s stock price was up 4.7% on Wednesday . The stock traded as high as $10.23 and last traded at $10.38. Approximately 137,645 shares changed hands during trading, a decline of 92% from the average daily volume of 1,650,801 shares. The stock had previously closed at $9.91.

Analysts Set New Price Targets

Several research analysts have recently issued reports on QURE shares. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, March 4th. Wells Fargo & Company dropped their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Finally, Leerink Partners upped their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Trading Up 7.7 %

The firm has a market cap of $577.27 million, a PE ratio of -2.16 and a beta of 0.37. The company’s fifty day moving average price is $13.60 and its two-hundred day moving average price is $10.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Buying and Selling at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently made changes to their positions in the stock. Twin Tree Management LP purchased a new stake in uniQure during the fourth quarter worth about $77,000. FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the 4th quarter valued at approximately $88,000. RTW Investments LP purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $49,000. ADAR1 Capital Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth approximately $177,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.